
    
      A 3-arm, double-blind, randomized, placebo-controlled, multicenter, fixed dose study to
      assess efficacy and safety of TC-5619 in adults with inattentive-predominant attention
      deficit/hyperactivity disorder (ADHD) utilizing the Connor's Adult ADHD Rating
      Scale-Investigator Completed Version (CAARS-INV) inattentive subscale scores through 4 weeks
      of treatment.
    
  